trial

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCTId NCT02748694
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 114 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2019-09-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
114 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-05-09
Primary completion
2019-09-22
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
TAK-041

Sponsors

Neurocrine BiosciencesLead Sponsor
TakedaCollaborator

Investigators

1
Medical Director Clinical ScienceStudy Director

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
114
Phase
PHASE1
Primary Completion Date
2019-09-22
Status
COMPLETED
relationships
The graph out of here
drug
TAK-041
drug
lead_sponsor
Neurocrine Biosciences
company
collaborator
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication
Healthy Volunteers
indication
investigator
Medical Director Clinical Science
person